Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8

August 28, 2017
Opdivo The health ministry will report to its key advisory committee on September 8 a plan to approve Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) for a new indication of gastric cancer, with its official green light expected within a month...read more